ArticleBlood advances2020
Survival following allogeneic transplant in patients with myelofibrosis.
Erratum issuedOpen access · goldAbstract readMulticenter Study
In one paragraph
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 48 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
7.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis.Annals of medicine · 2023Pooled it
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.Transplantation and cellular therapy · 2021Pooled it
- POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.Future oncology (London, England) · 2026Trial
- Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT.American journal of hematology · 2025Article
- SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms.Clinical lymphoma, myeloma & leukemia · 2025Review
- Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.American journal of hematology · 2025Review
- Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms.Cancers · 2025Review
- Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia.Haematologica · 2025Review
- Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes.Annals of hematology · 2025Review
- Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.Blood advances · 2025Article
- Reconstructing skeletal homeostasis through allogeneic hematopoietic stem cell transplantation in myelofibrosis.Nature communications · 2025Article
- Allogeneic Transplantation for Older Adults.Advances in experimental medicine and biology · 2025Review
- Myelofibrosis: Timing of Transplantation and Management of Splenomegaly.Advances in experimental medicine and biology · 2025Review
- Anemia and blood transfusions in myelofibrosis: economic and organizational impact on Italian patients, caregivers and hospitals.Frontiers in oncology · 2025Article
- Advances in Stem Cell Transplantation for Myelofibrosis.Current hematologic malignancy reports · 2024Review
- Treatment Strategies Used in Treating Myelofibrosis: State of the Art.Hematology reports · 2024Review
- Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study.Blood advances · 2024Article
- Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.Bone marrow transplantation · 2024Observational
- Myelofibrosis and allogeneic transplantation: critical points and challenges.Frontiers in oncology · 2024Review
- CALR mutations possess unique prognostic relevance in myelofibrosis-before and after transplant.Bone marrow transplantation · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
68 authors at 20 institutions in 11 countries.
Krisstina GowinDivision of Hematology and Oncology, University of Arizona, Tucson, AZ.
Karen BallenDivision of Hematology and Oncology, University of Virginia Health System, Charlottesville, VA.
Kwang Woo AhnCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Zhen-Huan HuCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Haris AliCity of Hope, Duarte, CA.
Murat O ArcasoyDivision of Hematology, Department of Medicine, Duke University School of Medicine, Durham, NC.
Rebecca DevlinUniversity Health Network, Toronto, ON, Canada.
Maria CoakleyInstitute of Cancer Research, Chelsea, London, United Kingdom.
Aaron T GerdsHematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Michael GreenDivision of Hematology, Department of Medicine, Duke University School of Medicine, Durham, NC.
Vikas GuptaPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Gabriela HobbsMassachusetts General Hospital, Boston, MA.
Tania JainMemorial Sloan Kettering Cancer Center, New York, NY.
Malathi KandarpaDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.
Rami KomrokjiMoffitt Cancer Center, Tampa, FL.
Andrew T KuykendallMoffitt Cancer Center, Tampa, FL.
Kierstin LuberDepartment of Osteopathic Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO.
Lucia MasarovaMD Anderson Cancer Center, Houston, TX.
Laura C MichaelisHematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, WI.
Sarah PatchesDana-Farber Cancer Institute, Boston, MA.
Ashley C PariserNorthwestern Memorial Hospital, Chicago, IL.
Raajit RampalMemorial Sloan Kettering Cancer Center, New York, NY.
Brady SteinNorthwestern Memorial Hospital, Chicago, IL.
Moshe TalpazMD Anderson Cancer Center, Houston, TX.
Srdan VerstovsekMD Anderson Cancer Center, Houston, TX.
Martha WadleighDana-Farber Cancer Institute, Boston, MA.
Vaibhav AgrawalDivision of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, IN.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
Miguel Angel DiazDepartment of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
Belinda R AvalosDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Carolinas HealthCare System, Charlotte, NC.
Ulrike BacherDepartment of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Asad BasheyBlood and Marrow Transplant Program at Northside Hospital, Atlanta, GA.
Amer M BeitinjanehDepartment of Medicine, University of Miami, Miami, FL.
Jan CernyDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, MA.
Saurabh ChhabraCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Edward CopelanLevine Cancer Institute, Atrium Health, Carolinas HealthCare System, Charlotte, NC.
Corey S CutlerDepartment of Medical Oncology, Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA.
Zachariah DeFilippBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA.
Shahinaz M GadallaDivision of Cancer Epidemiology & Genetics, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Rockville, MD.
Siddhartha GangulyDivision of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS.
Michael R GrunwaldDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Carolinas HealthCare System, Charlotte, NC.
Shahrukh K HashmiDepartment of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
Mohamed A Kharfan-DabajaDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL.
Tamila Kindwall-KellerDivision of Hematology and Oncology, University of Virginia Health System, Charlottesville, VA.
Nicolaus KrögerDepartment of Stem Cell Transplantation, University Hospital Hamburg, Hamburg, Germany.
Hillard M LazarusDepartment of Medicine, Case Western Reserve University, Cleveland, OH.
Jane L LiesveldDepartment of Medicine, University of Rochester Medical Center, Rochester, NY.
Mark R LitzowDivision of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN.
David I MarksAdult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
Sunita NathanRush University Medical Center, Chicago, IL.
Taiga NishihoriDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Richard F OlssonDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Attaphol PawarodeBlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI.
Jacob M RoweDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Mary Lynn SavoieTom Baker Cancer Centre, Calgary, AB, Canada.
Sachiko SeoDepartment of Haematology and Oncology, Dokkyo Medical University; Tochigi, Japan.
Melhem SolhThe Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA.
Roni TamariMemorial Sloan Kettering Cancer Center, New York, NY.
Leo F VerdonckDepartment of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands.
Jean A YaredBlood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD.
Edwin AlyeaCenter of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA.
Uday PopatMD Anderson Cancer Center, Houston, TX.
Ronald SobecksCleveland Clinic, Cleveland, OH.
Bart L ScottFred Hutchinson Cancer Research Center, Seattle, WA.
Ryotaro NakamuraDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA; and.
Ruben MesaUT Health San Antonio MD Anderson, San Antonio, TX.
Wael SaberCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Medical College of Wisconsin · USDana-Farber Cancer Institute · USThe University of Texas MD Anderson Cancer Center · USCarolinas Healthcare System · USMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USCity of Hope · USCleveland Clinic · USDuke University · USKing Faisal Specialist Hospital & Research Centre · SAMassachusetts General Hospital · USNorthside Hospital · USNorthwestern Memorial Hospital · USUniversity of Michigan · USUniversity of Virginia Health System · USCase Western Reserve University · USDokkyo Medical University · JPFred Hutch Cancer Center · USHospital Infantil Universitario Niño Jesús · ESIndiana University School of Medicine
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MBlood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4MTISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1MTherapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2MRandomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiencyU01AI126612 · NIAID · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S, PULSIPHER, MICHAEL A · 2017 to 2023
$8.5MThe role of TCOF1 in germline predisposition to and in leukemic transformation of chronic myelomonocytic leukemiaR01CA152108 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jing Zhang · 2011 to 2026
$5.4MIdentifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell DonorsR01HL131731 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PULSIPHER, MICHAEL A, SWITZER, GALEN E. · 2018 to 2022
$3.6MSelection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA GenotypesR01HL129472 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI HSU, KATHARINE C · 2015 to 2019
$2.6MHematopoietic Stem Cell Transplantation for Young Adults with SCD - DCCU01HL128568 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI EAPEN, MARY, MENDIZABAL, ADAM M. · 2015 to 2019
$1.7MCost Effectiveness Analysis of Stem Cell Transplant in Older MDS PatientsR01HL126589 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RAMSEY, SCOTT D., SABER, WAEL · 2015 to 2018
$1.7MNCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA152108NCI NIH HHS R01 CA231141NCI NIH HHS U24 CA076518NHLBI NIH HHS R01 HL126589NHLBI NIH HHS R01 HL129472NHLBI NIH HHS R01 HL131731NHLBI NIH HHS R21 HL140314NHLBI NIH HHS U01 HL128568NHLBI NIH HHS U24 HL138660NIAID NIH HHS U01 AI126612
Abstract
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.
Indexed as
Hematopoietic Stem Cell TransplantationPrimary MyelofibrosisHumansPrognosisRetrospective StudiesTransplantation, Homologous
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.